<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; ABMD</title>
	<atom:link href="http://www.stockbloghub.com/tag/abmd/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MDT) MedTech Industry Stock Outlook &#8211; March 2012 &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2012/03/19/mdt-medtech-industry-stock-outlook-march-2012-zacks-analyst-interviews/94611</link>
		<comments>http://www.stockbloghub.com/2012/03/19/mdt-medtech-industry-stock-outlook-march-2012-zacks-analyst-interviews/94611#comments</comments>
		<pubDate>Tue, 20 Mar 2012 02:13:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94611</guid>
		<description><![CDATA[Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure volume pressures. The difficult macroeconomic backdrop, pricing headwinds, austerity measures, reimbursement pressure, a still unstable job market and the impact of health care reform continue to weigh on the medical devices industry, exacerbated by Europe&#8217;s sovereign debt plight. With fewer patients going under the knife accompanied by concerns of overuse of devices, companies in the cardiovascular and orthopedic domain continue to grapple with tepid utilization. After having a buoyant first half, the MedTech sector went through a rough patch in the back half of 2011 given the weakened sector fundamentals, sluggish key end-markets ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/19/mdt-medtech-industry-stock-outlook-march-2012-zacks-analyst-interviews/94611/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) MedTech Industry Stock Outlook &#8211; March 2012 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2012/03/08/mdt-medtech-industry-stock-outlook-march-2012-industry-outlook/94609</link>
		<comments>http://www.stockbloghub.com/2012/03/08/mdt-medtech-industry-stock-outlook-march-2012-industry-outlook/94609#comments</comments>
		<pubDate>Thu, 08 Mar 2012 19:28:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94609</guid>
		<description><![CDATA[Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure volume pressures. The difficult macroeconomic backdrop, pricing headwinds, austerity measures, reimbursement pressure, a still unstable job market and the impact of health care reform continue to weigh on the medical devices industry, exacerbated by Europe&#8217;s sovereign debt plight. With fewer patients going under the knife accompanied by concerns of overuse of devices, companies in the cardiovascular and orthopedic domain continue to grapple with tepid utilization. After having a buoyant first half, the MedTech sector went through a rough patch in the back half of 2011 given the weakened sector fundamentals, sluggish key end-markets ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/08/mdt-medtech-industry-stock-outlook-march-2012-industry-outlook/94609/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABMD) Abiomed Sees Positive USpella Device Data</title>
		<link>http://www.stockbloghub.com/2011/12/01/abmd-abiomed-sees-positive-uspella-device-data/87836</link>
		<comments>http://www.stockbloghub.com/2011/12/01/abmd-abiomed-sees-positive-uspella-device-data/87836#comments</comments>
		<pubDate>Thu, 01 Dec 2011 15:01:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[THOR]]></category>
		<category><![CDATA[Thoratec Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87836</guid>
		<description><![CDATA[Massachusetts-based cardiac assist devices maker Abiomed (ABMD) reported encouraging clinical data from the prophylactic use of its Impella 2.5 cardiac pumps in complex coronary interventions. Results from the company’s USpella multi-center observational registry, published in the December edition of the Catheterization and Cardiovascular Interventions Journal, showed that patients receiving percutaneous revascularization with Impella 2.5 support achieved a statistically significant improvement in left ventricle ejection fraction (“LVEF”). LVEF is a measure of the amount of blood beingpumped out of the left ventricle (the main pumping chamber) with each beat. Moreover, there was a considerable improvement of the functional heart failure status in one or more New York Heart Association (“NYHA”) classes (classification representing stages of heart failure). The results further validate the effectiveness and viability of Impella 2.5. Abiomed recently published ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/01/abmd-abiomed-sees-positive-uspella-device-data/87836/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Technology Industry Stock Outlook &#8211; November 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069</link>
		<comments>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069#comments</comments>
		<pubDate>Fri, 18 Nov 2011 18:52:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[THOR]]></category>
		<category><![CDATA[Thoratec Corporation]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87069</guid>
		<description><![CDATA[The performance of incumbent players in the MedTech industry continued to be hamstrung by a spate of macro issues (including sustained price and procedure volume pressures) in the September quarter. The prevailing macroeconomic factors, pricing headwinds, austerity measures, reimbursement pressure and the impact of health care reform continues to weigh on the medical devices industry, exacerbated by Europe&#8217;s sovereign debt plight. The beleaguered U.S. implantable defibrillator market continues to bother cardiac devices makers, as reflected by sustained implant volume pressure. On the other hand, companies in the orthopedic domain remain affected by a still choppy reconstructive implant market as they faced sustained pressure across hip, knee and spine businesses in the third quarter (albeit to a lesser extent vis-à-vis the sequentially prior quarter). Although a number of these issues are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Stock Outlook &#8211; Sept. 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/08/mdt-medical-devices-stock-outlook-sept-2011-industry-outlook/82743</link>
		<comments>http://www.stockbloghub.com/2011/09/08/mdt-medical-devices-stock-outlook-sept-2011-industry-outlook/82743#comments</comments>
		<pubDate>Thu, 08 Sep 2011 19:53:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82743</guid>
		<description><![CDATA[June quarter results mostly mirror the preceding quarter as a host of macro headwinds (including price and procedure volume pressures) continued to haunt the MedTech industry and weighed on the performance of the incumbent players. Although a number of these issues are expected to linger over the second-half of 2011, the industry is expected to fare relatively better this year thanks to several tailwinds and growth opportunities. Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative, with estimated worldwide sales of more than $300 billion in 2011. The U.S. is the largest market, with estimated sales of roughly $95 billion in 2010. The highly-regulated medical devices industry is divided into different segments including Cardiology, Oncology, Neuro, Orthopedic and Aesthetic Devices. The U.S. medical devices ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/08/mdt-medical-devices-stock-outlook-sept-2011-industry-outlook/82743/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/22/mdt-medical-devices-stock-outlook-june-2011-industry-outlook/77179</link>
		<comments>http://www.stockbloghub.com/2011/06/22/mdt-medical-devices-stock-outlook-june-2011-industry-outlook/77179#comments</comments>
		<pubDate>Thu, 23 Jun 2011 01:09:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[S]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[Sprint Nextel Corporation]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77179</guid>
		<description><![CDATA[A host of macro headwinds (including price and procedure volume pressure) which hit the MedTech industry last year continued to haunt the sector during the March quarter and encumber growth. Although a number of these issues are expected to linger through the remainder of 2011, the industry is expected to fare relatively better this year thanks to several tailwinds and growth opportunities. Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative, with estimated worldwide sales of more than $300 billion in 2011. The U.S. is the largest market, with estimated sales of roughly $95 billion in 2010. The medical devices industry is divided into different segments including Cardiology, Oncology, Neuro, Orthopedic and Aesthetic Devices. The U.S. medical devices industry continues to grow at a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/mdt-medical-devices-stock-outlook-june-2011-industry-outlook/77179/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Industry Outlook &#8211; April 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/03/31/mdt-medical-devices-industry-outlook-april-2011-industry-outlook/70413</link>
		<comments>http://www.stockbloghub.com/2011/03/31/mdt-medical-devices-industry-outlook-april-2011-industry-outlook/70413#comments</comments>
		<pubDate>Thu, 31 Mar 2011 23:07:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[Allscripts-Misys Healthcare Solutions Inc]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Cyberonics Inc]]></category>
		<category><![CDATA[CYBX]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[QSII]]></category>
		<category><![CDATA[Quality Systems Inc.]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[TOMO]]></category>
		<category><![CDATA[TomoTherapy Incorporated]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70413</guid>
		<description><![CDATA[Last year was challenging for medical device companies given the exigent economic conditions and an uncertain healthcare environment. The MedTech industry was hit by several macro headwinds in 2010 including price/volume and utilization pressure and a more restrictive regulatory environment. Although a number of these issues remain, the industry is expected to fare better this year due to several tailwinds and growth opportunities. Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative, with estimated worldwide sales of more than $300 billion in 2011. The U.S. is the largest medical devices market, with estimated sales of roughly $95 billion in 2010. The medical devices industry is divided into different segments such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices and Healthcare IT (“HCIT”). The U.S. medical ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/31/mdt-medical-devices-industry-outlook-april-2011-industry-outlook/70413/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Industry Outlook December 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/12/06/mdt-medical-devices-industry-outlook-december-2010-industry-outlook/61379</link>
		<comments>http://www.stockbloghub.com/2010/12/06/mdt-medical-devices-industry-outlook-december-2010-industry-outlook/61379#comments</comments>
		<pubDate>Tue, 07 Dec 2010 01:15:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[Allscripts-Misys Healthcare Solutions Inc]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Cyberonics Inc]]></category>
		<category><![CDATA[CYBX]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MDRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[QSII]]></category>
		<category><![CDATA[Quality Systems Inc.]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=61379</guid>
		<description><![CDATA[Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative with 2009 worldwide sales in excess of $220 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different segments such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices and Healthcare IT (“HCIT”). The U.S. medical devices industry continues to grow at a brisk rate, thanks to an aging Baby Boomer population, high unmet medical needs and increased incidence of lifestyle diseases (including cardiovascular diseases, diabetes, hypertension and obesity). Neuro, Orthopedic and Aesthetic represent the fastest growing categories. The aging population represents a major catalyst for demand of medical devices. The elderly population (persons 65 years and above) base in the U.S. registered 39.6 million in 2009, representing roughly 13% of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/06/mdt-medical-devices-industry-outlook-december-2010-industry-outlook/61379/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABMD) Abiomed&#8217;s Quarterly Loss Slightly Larger Than Expected</title>
		<link>http://www.stockbloghub.com/2010/05/20/abmd-abiomeds-quarterly-loss-slightly-larger-than-expected/37771</link>
		<comments>http://www.stockbloghub.com/2010/05/20/abmd-abiomeds-quarterly-loss-slightly-larger-than-expected/37771#comments</comments>
		<pubDate>Thu, 20 May 2010 20:38:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37771</guid>
		<description><![CDATA[Abiomed Inc. (ABMD) reported a net loss of 13 cents per share for the fourth quarter fiscal 2010, marginally higher than the Zacks Consensus Estimate of a loss of 12 cents per share but lower than the year-ago loss of 16 cents. For fiscal 2010, the loss was 46 cents per share, considerably lower than the Zacks Consensus Estimate and the year-ago loss of 66 cents and 61 cents, respectively. Quarterly Results Total revenues in the fourth quarter increased 17% year over year to roughly $23.0 million. Growth was led by higher demand for the company’s Impella products. In the fourth quarter, roughly 545 commercial patients in the U.S. were treated with Abiomed’s Impella products, compared with 261 in the year-ago quarter. Worldwide, Impella revenues increased 49% year over year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/20/abmd-abiomeds-quarterly-loss-slightly-larger-than-expected/37771/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NEWS) Five stocks for Wednesday: March 3, 2010</title>
		<link>http://www.stockbloghub.com/2010/03/04/news-five-stocks-for-wednesday-march-3-2010/29682</link>
		<comments>http://www.stockbloghub.com/2010/03/04/news-five-stocks-for-wednesday-march-3-2010/29682#comments</comments>
		<pubDate>Thu, 04 Mar 2010 16:46:23 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[Actel Corporation]]></category>
		<category><![CDATA[ACTL]]></category>
		<category><![CDATA[CODI]]></category>
		<category><![CDATA[Compass Diversified Holdings]]></category>
		<category><![CDATA[COO]]></category>
		<category><![CDATA[news]]></category>
		<category><![CDATA[NewStar Financial]]></category>
		<category><![CDATA[The Cooper Companies Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29682</guid>
		<description><![CDATA[On my blog Financial Tides I like to start out the day by screening on Barchart for some stocks I might consider buying that day. I look for stocks that have been having recent price appreciation, are projected to have increases in sales and earnings and have some positive investor sentiment. I then take that list and research further. I&#8217;ll start sharing that list with you each morning. Cooper Companies (COO) &#8212; through its principal subsidiaries, develops, manufactures and markets healthcare products. CooperVision markets a range of contact lenses to correct visual defects, specializing in toric lenses that correct astigmatism. The company also markets conventional toric and spherical lenses and lenses for patients with more complex vision disorders. CooperSurgical markets diagnostic products, surgical instruments and accessories to the women&#8217;s healthcare ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/04/news-five-stocks-for-wednesday-march-3-2010/29682/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABMD) Abiomed Beats Consensus Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2010/02/08/abmd-abiomed-beats-consensus-earnings-estimates/27324</link>
		<comments>http://www.stockbloghub.com/2010/02/08/abmd-abiomed-beats-consensus-earnings-estimates/27324#comments</comments>
		<pubDate>Mon, 08 Feb 2010 18:16:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27324</guid>
		<description><![CDATA[Abiomed, Inc. (ABMD) reported third quarter of fiscal 2010 results. For the quarter, net loss per share was 11 cents, beating the Zacks Consensus Estimate of loss per share of 18 cents and the year-ago loss of 20 cents. Earnings Estimate Revision Trend and Zacks Rank The earnings estimate revision for Abiomed has demonstrated a mixed trend in the past 30 days. During the period, one out of eleven analysts has downgraded his earnings estimate while none upgraded his estimate for the fourth quarter of fiscal 2010. There were no estimates revisions from the seven analysts tracking the stock for the first quarter of fiscal 2011. For fiscal 2010 and fiscal 2011, only one out of twelve analysts has downgraded and upgraded his earnings estimates for full year, respectively. The mixed trend ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/08/abmd-abiomed-beats-consensus-earnings-estimates/27324/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABMD) Abiomed Reports Preliminary Results</title>
		<link>http://www.stockbloghub.com/2010/01/11/abmd-abiomed-reports-preliminary-results/24630</link>
		<comments>http://www.stockbloghub.com/2010/01/11/abmd-abiomed-reports-preliminary-results/24630#comments</comments>
		<pubDate>Mon, 11 Jan 2010 22:41:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24630</guid>
		<description><![CDATA[Abiomed, Inc. (ABMD) reported preliminary results for the third quarter of fiscal 2010. Total revenues were roughly $22.8 million, an increase of 32% year over year and were at a record high. The company will report full results for the third quarter on Feb 4, 2010. Worldwide Impella revenues increased 81% year over year to $15.9 million. U.S. Impella revenues constituted approximately 91% of total worldwide Impella revenues and increased 116% year over year. Non-Impella revenues declined 18% year over year to $6.9 million. Cash burn for the reported quarter was lower at $0.6 million, compared to $2.5 million in the year-ago quarter. Cash, cash equivalents, short and long-term marketable securities totaled $51.7 million, compared to $52.3 million at the end of the previous quarter. Abiomed reported that roughly 425 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/11/abmd-abiomed-reports-preliminary-results/24630/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABMD) Abiomed, Inc&#8217;s Loss Narrower than Expected</title>
		<link>http://www.stockbloghub.com/2009/11/08/abmd-abiomed-incs-loss-narrower-than-expected/19896</link>
		<comments>http://www.stockbloghub.com/2009/11/08/abmd-abiomed-incs-loss-narrower-than-expected/19896#comments</comments>
		<pubDate>Mon, 09 Nov 2009 02:38:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19896</guid>
		<description><![CDATA[Abiomed, Inc. (ABMD) reported fiscal second-quarter loss of 14 cents per share, considerably better than the Zacks Consensus Estimate of a loss of 21 cents. However, loss per share in the year-ago quarter was 8 cents. Total revenues in the reported quarter were roughly flat year over year at $20 million. In terms of products: Worldwide Impella revenues increased 26% year over year to $13.2 million. Non-Impella revenues declined 28% year over year to $6.8 million. Abiomed witnessed a strong demand for its Impella products in the domestic market. Total Impella revenues in the U.S. increased 95% year over year to $12.1 million. This was backed by strong commercial reorders in the U.S. market which increased 230% year over year to $6.6 million. In terms of operational metrics: the number ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/08/abmd-abiomed-incs-loss-narrower-than-expected/19896/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

